CytomX Therapeutics to Present at Upcoming September Investor Conferences
CytomX Therapeutics (NASDAQ: CTMX), a leader in masked, conditionally activated biologics, has announced its participation in three major investor conferences this September in New York.
The company will present at the Cantor Global Healthcare Conference (September 4), the H.C. Wainwright Global Investment Conference (September 9), and the Morgan Stanley Global Healthcare Conference (September 10). All presentations will be available via webcast on the company's website, and management will be available for one-on-one meetings with registered conference attendees.
CytomX Therapeutics (NASDAQ: CTMX), azienda di riferimento nel settore dei biologici mascherati e attivati in modo condizionale, ha comunicato la sua partecipazione a tre importanti conferenze per investitori che si terranno a New York questo settembre.
La società presenterà al Cantor Global Healthcare Conference (4 settembre), al H.C. Wainwright Global Investment Conference (9 settembre) e al Morgan Stanley Global Healthcare Conference (10 settembre). Tutte le presentazioni saranno trasmesse in webcast sul sito aziendale e il management sarà disponibile per incontri one-to-one con i partecipanti registrati alle conferenze.
CytomX Therapeutics (NASDAQ: CTMX), líder en biológicos enmascarados y activados condicionalmente, ha anunciado su participación en tres importantes conferencias para inversores en Nueva York este septiembre.
La compañía presentará en la Cantor Global Healthcare Conference (4 de septiembre), en la H.C. Wainwright Global Investment Conference (9 de septiembre) y en la Morgan Stanley Global Healthcare Conference (10 de septiembre). Todas las presentaciones estarán disponibles en webcast en la web de la compañía y la dirección estará disponible para reuniones individuales con los asistentes registrados a las conferencias.
CytomX Therapeutics (NASDAQ: CTMX)는 마스크된 조건부 활성화 바이오의약품 분야의 선도기업으로, 이번 9월 뉴욕에서 열리는 3개의 주요 투자자 컨퍼런스에 참가한다고 발표했습니다.
회사는 Cantor Global Healthcare Conference(9월 4일), H.C. Wainwright Global Investment Conference(9월 9일), Morgan Stanley Global Healthcare Conference(9월 10일)에서 발표를 진행합니다. 모든 발표는 회사 웹사이트를 통해 웹캐스트로 제공되며, 경영진은 등록된 컨퍼런스 참석자와의 1:1 미팅도 진행할 예정입니다.
CytomX Therapeutics (NASDAQ: CTMX), leader dans les biologiques masqués et activables de façon conditionnelle, a annoncé sa participation à trois grandes conférences pour investisseurs à New York ce mois de septembre.
La société présentera lors de la Cantor Global Healthcare Conference (4 septembre), de la H.C. Wainwright Global Investment Conference (9 septembre) et de la Morgan Stanley Global Healthcare Conference (10 septembre). Toutes les présentations seront diffusées en webcast sur le site de la société et la direction sera disponible pour des réunions individuelles avec les participants inscrits aux conférences.
CytomX Therapeutics (NASDAQ: CTMX), ein führendes Unternehmen für maskierte, bedingt aktivierbare Biologika, hat seine Teilnahme an drei bedeutenden Investorenkonferenzen in New York im September angekündigt.
Das Unternehmen wird auf der Cantor Global Healthcare Conference (4. September), der H.C. Wainwright Global Investment Conference (9. September) und der Morgan Stanley Global Healthcare Conference (10. September) präsentieren. Alle Präsentationen werden per Webcast auf der Firmenwebsite verfügbar sein, und das Management steht für Einzelgespräche mit registrierten Konferenzteilnehmern zur Verfügung.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September.
Cantor Global Healthcare Conference 2025
Date: Thursday, September 4, 2025
Fireside Chat: 8:35 a.m. ET
Location: New York, NY
H.C. Wainwright 27th Annual Global Investment Conference
Date: Tuesday, September 9, 2025
Formal Presentation: 11:30 a.m. ET
Location: New York, NY
Morgan Stanley 23rd Annual Global Healthcare Conference
Date: Wednesday, September 10, 2025
Fireside Chat: 1:05 p.m. ET
Location: New York, NY
A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conference.
About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY® therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s multi-modality technology platform has produced therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. CytomX’s current clinical-stage pipeline includes CX-2051 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM), armed with a topoisomerase-1 inhibitor payload. CX-2051 has potential applicability across multiple EpCAM-expressing epithelial cancers, including CRC, and was discovered in collaboration with ImmunoGen. CX-801 is a masked interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).
Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com
Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
stephanie.ascher@precisionaq.com
Media Contact:
Redhouse Communications
Teri Dahlman
teri@redhousecomms.com
FAQ
When is CytomX Therapeutics (CTMX) presenting at the Cantor Global Healthcare Conference 2025?
What time is CytomX's presentation at the H.C. Wainwright Conference 2025?
How can investors watch CytomX's conference presentations in September 2025?
Will CytomX management be available for individual investor meetings at the September 2025 conferences?
